文献速递结核与非结核分枝杆菌

序贯单药治疗鸟分枝杆菌肺感染的小鼠模型疗效

Efficacies of Sequenced Monotherapies of Mycobacterium avium Lung Infection in Mouse.
PubMed 文献 · J Infect Dis · 2026-01-01

该研究在小鼠慢性鸟分枝杆菌肺感染模型中比较序贯单药(克拉霉素、贝达喹啉、氯法齐明每4周轮换)与标准三联方案(克拉霉素、乙胺丁醇、利福平)的疗效。结果显示序贯单药降低肺菌量效果与三联方案相当,并防止肺外播散,且未出现对三种药物的MIC升高,提示序贯单药不诱导耐药。

要点

  • 序贯单药降低肺菌量效果与标准三联方案相当
  • 序贯单药可防止肺外播散
  • 序贯单药未筛选出对克拉霉素、贝达喹啉或氯法齐明的耐药

核心结论

  • 序贯单药治疗鸟分枝杆菌肺感染可达到与多药方案相当的疗效且不促进耐药。

研究设计与样本

  • 在验证的小鼠慢性鸟分枝杆菌肺感染模型中,比较标准三联方案(克拉霉素、乙胺丁醇、利福平)与序贯单药(克拉霉素、贝达喹啉、氯法齐明每4周轮换)的疗效。

主要发现

  • 序贯单药降低肺菌量效果与标准三联方案相当,并防止肺外播散。
  • 治疗各阶段分离菌对克拉霉素、贝达喹啉和氯法齐明的MIC未见升高,提示未筛选耐药克隆。

关键数值与推荐

  • 序贯单药每4周轮换一种药物,依次为克拉霉素、贝达喹啉、氯法齐明。
  • 标准三联方案为克拉霉素、乙胺丁醇和利福平。

临床怎么用

  • 为鸟分枝杆菌肺病提供一种可能更耐受的替代策略,但需进一步临床研究验证。

局限性

  • 研究为小鼠模型中的概念验证,结论需在人体研究中确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The incidence of nontuberculous mycobacterial (NTM) infections has been rising and now exceeds tuberculosis in several countries. Mycobacterium avium is the most common NTM cause of chronic lung disease. Current guidelines recommend simultaneous administration of three or more antibiotics, modeled after tuberculosis treatment, but these regimens are limited by toxicity, poor adherence, and low cure rates. Importantly, unlike M. tuberculosis, M. avium is acquired from the environment rather than transmitted between humans, weakening the rationale for multidrug therapy as necessary to suppress resistance. METHODS: To test an alternative treatment approach, we evaluated sequential monotherapy in a validated murine model of chronic M. avium lung infection. Mice were treated with either the standard triple-drug regimen of clarithromycin, ethambutol, and rifampicin or with sequential monotherapy: clarithromycin, bedaquiline, and clofazimine, with only one drug administered at a time for 4-week intervals. Lung and spleen bacterial burdens were quantified, and minimum inhibitory concentrations (MICs) were determined for isolates recovered during treatment to assess resistance emergence. RESULTS: Sequential monotherapy achieved reductions in lung bacterial burden equivalent to those of the standard multidrug regimen and prevented extrapulmonary dissemination. Notably, no increase in MICs was observed for clarithromycin, bedaquiline, or clofazimine across treatment phases, indicating that sequential monotherapy did not select for resistant clones. CONCLUSIONS: These findings provide the first evidence that sequential monotherapy can deliver efficacy comparable to multidrug therapy for M. avium disease without promoting resistance. This proof-of-concept supports further investigation of sequencing strategies as a potentially more tolerable alternative to current triple-agent regimens.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Howe RA, Rimal B, Khandelwal J, et al. Efficacies of Sequenced Monotherapies of Mycobacterium avium Lung Infection in Mouse. J Infect Dis. 2026. PMID: 41416484. doi:10.1093/infdis/jiaf640

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。